The FDA has accepted for review a new drug application (NDA) for UGN-103, an investigational intravesical formulation of ...

Ryan Moore, MD, discusses the choice between surgery and total neoadjuvant therapy (TNT) for rectal cancer and when watch-and ...

SABR improved recurrence-free survival vs historical benchmark with IVC tumor thrombus; investigators hypothesize this could ...

Selpercatinib (Retevmo), a selective oral RET inhibitor, demonstrated durable antitumor activity and a manageable safety ...

The phase 2 PEGASUS trial of ctDNA-guided adjuvant therapy in high-risk stage II/III colon cancer missed its primary end ...

Ashley Rosko, MD, discusses how telehealth can improve access to myeloma transplant evaluation, reduce care disparities, and ...

Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether ...

Elevar Therapeutics and Hengrui Pharma have resubmitted applications to the FDA seeking approval of rivoceranib plus ...

Explore why some patients with multiple myeloma miss stem cell transplant, spotlighting age, race and socioeconomic barriers, ...

The addition of carotuximab (ENV-105) to apalutamide (Erleada) significantly improved progression-free survival (PFS) ...

Mogamulizumab (Poteligeo) was associated with durable real-world treatment outcomes in patients with mycosis fungoides (MF) ...

Otero, MD, discusses how T-cell–engaging therapies are aiming to meaningfully impact or negate the disease course of ...